Post No. 2,303 The following is brought to you by Intellivest Securities Research, Inc. Toward the end of this Blog is a list of the Dow 30 current CEOs, and a recent ranking of the Dow 30 components by market capitalization and recent Dow 30 components' SEC filings.
A read of the print editions of Wednesday's Wall St. Journal, Financial Times, Investor's Business Daily, New York Times, USA Today, Atlanta Journal & amp; amp; Constitution & Daily Report (Ga. - carries Bloomberg) yielded the following stories about Dow Jones Industrial Average 30 component companies and the Dow with stories about the Dow aggregated first and then items about Dow Jones Industrial Average 30 companies presented alphabetically, followed by a separate table of Dow component's symbol and Tuesday's stock prices and related data in alphabetical order.
The Dow Jones Industrial Average: The Dow Jones Industrial Average closed Tuesday at 15520.59 down 1.38 or 0.01% from Monday's close of 15521.97. For the year the Dow is up 18.44%. Of the Dow components 14 gained and 16 declined. The biggest gainer dollar-wise was Boeing up 92 cents and percentage-wise was Cisco up 1.34% . The biggest decliner dollar-wise and percentage-wise was Verizon down $1.07 or 2.08%.
WSJ pC4 "Dow industrials tip lower" by Tomi Kilgore says the Dow was down as investors balanced data showing a strong rise in home prices vs. a slip in consumer confidence & mixed corp earnings. Pfizer rose 13 cents after it reported 2Q earnings above analyst forecasts, offsetting rev that fell shy of forecasts. Merck fell 29 cents as earnings and rev dropped from year earlier levels.
NYT pB9 "Market closes tightly mixed after day of wary trading" by AP says Wall St lacked direction Tues as it awaited the week's main economic news & the stock market wandered between slight gains & losses before closing barely higher.
FT p20 Pfizer boosted by strong earnings as pharmas support S&P 500" by Jason Abbruzzese says Pfixer and Merck highlighted the mixed earnings season as Pfizer reported 2Q earnings that beat estimates while Merck missed expectations on rev and earnings per share.
IBD pB4 "nasdaq posts new high but S&P only breaks even" by Paul Whitfield says stocks were flat to up in rising vol Tes as the current outlook is a confirmed uptrend.
As of the open of the market on Wednesday the current divisor for the Dow Jones Industrial Average found at page C5 of Wednesday's Wall St. Journal is 0.130216081. Wednesday's trailing P/E ratio is 16.69 up from yesterday's trailing P/E ratio of 16.66 (last year it was 14.21); today's P/E estimate is 13.90 unchanged from Tuesday's P/E estimate of 13.90 (year ago it was 12.45) and today's dividend yield is 2.37 unchanged from yesterday's dividend yield of 2.37 (last year it was 2.58). The Dow's all-time high was 15,567.74 on July 23, 2013. The 12 year low close for the Dow was on March 9, 2009 when it fell to 6,547.05.
Tuesday's Dow Jones Industrial Average closing numerator was 2021.03 down 0.18 from Monday's losing numerator of 2021.21. This is the sum of all 30 closing prices. A short cut to the Dow numerator is to multiply the closing Dow by the Divisor. Now, if you divide the Dow numerator change for today by the divisor (0.130216081) you get the change in today's Dow. A dollar increase or decrease in a Dow stock results in a $7.68 change in the Dow Index.
The average closing price (the closing numerator divided by 30) of Tuesday's Dow Jones Industrial Average was $67.37 unchanged from Monday's average of $67.373. The median closing price of Tuesday's Dow Jones Industrial Average was $68.23 (DIS/UNH) down 47 cents from Monday's median closing price of $68.70. The lowest volume was 3M and the highest volume again was Bank of America.
If Tuesday morning before the market opened you had purchased 100 shares of each of the Dow Jones Industrial Average 30 shares (assuming you could buy fractional shares and assuming no transaction costs or dividends) and sold at the close you would have lost $18 ($202,121- $202,103).
MarketWatch 7/30/13 Tues. 4:28 pm by Kate Gibson & Victor Reklaitis says U.S. stocks ended slightly higher on Tuesday, with the Nasdaq Composite positioned for its best monthly performance since January 2012, as investors mostly adopted a cautious tone a day ahead of a monetary-policy decision from the Federal Reserve. Of the 304 companies that have reported earnings results for the second quarter, 201 have beaten estimates, 76 have missed, and 27 have met, producing a a beat rate of 66%, above the historical average, according to research by Christine Short, an associate director S&P Capital IQ. “Earnings so far are better than expected, but we haven’t seen much in the way of revenue figures,” said Robert Pavlik, chief market strategist at Banyan Partners LLC. What’s News: J.P. Morgan agrees to pay $410 million to regulators to settle allegations of electricity market manipulation. President Obama to offer ‘grand bargain’ on corporate taxes and jobs. Pfizer’s profits quadruple; Merck’s profits halved. All workers found after Florida plant blast. After a 72-point gain and a 43-point drop, the Dow Jones Industrial Average DJIA -0.0089% ended off 1.38 points at 15,520.59. Pfizer Inc. PFE +0.44% rose 0.4% after the drug maker and Dow component posted second-quarter results. The S&P 500 index SPX +0.04% advanced nearly 1 point to 1,685.96, with technology leading sector gains and telecommunications falling hardest. The Nasdaq Composite /quotes/zigman/12633936 COMP +0.48% climbed 17.33 points, or 0.5%, to 3,616.47, with the technology laden index up 6.3% for July, on track for its best monthly performance since January 2012. Advancers pulled just ahead of decliners on the New York Stock Exchange, where almost 678 million shares traded. Composite volume neared 3.3 billion. On Monday, composite volume on the Nyse came in just under 2.8 billion, the seventh lowest volume day so far this year.
The solid housing recovery is supporting further gains in home prices, according to the Standard & Poor's/Case-Shiller report released Tuesday.“People are a little skeptical here, there’s a pattern that is raising questions for the overall market, whether we can continue the trend of gains without any kind of give back,” said Pavlik, referring to a market that is up 18% for the year. The dollar DXY +0.15% gained against the currencies of major U.S. trading partners and the yield on the benchmark 10-year note 10_YEAR -0.08% held flat at 2.604%. Oil futures CLU3 -1.42% dropped $1.47, or 1.4%, to $103.08 a barrel and gold pricesGCZ3 -0.24% declined $4.80, or 0.4%, to $1,325.80 an ounce on the New York Mercantile Exchange. Community Heath Systems Inc. CYH -3.49% fell 3.5% after the for-profit hospital operator said it would buy competitor Health Management Associates Inc. HMA -10.86% for $3.9 billion. Shares of Health Management Associates slid nearly 11% after the company said it had received more subpoenas from regulators seeking information about its doctor relationships and some of its emergency-room operations.
Wednesday's Dow News followed by Tuesday's Closing Dow Numbers:
AT&T: WSJ pC2 "National rollout ready" by Robin Sidel says Isis, a jv, between AT&T, T-Mobile and Verizon, is a fledgling mobile payments system that will launch later this year.
Alcoa: No mentions found.
American Express: No mentions found.
Bank of America: No mentions found.
Boeing: No mentions found.
Caterpillar: No mentions found.
Chevron: NYT pC1 "An avenger on the defensive" by Clifford Krauss says the lawyer who beat Chevron in Ecudador and won an $18 bil judgment is defending himself against extortion charges brought by Chevron.
Cisco: No mentions found.
Coke: No mentions found.
Disney: No mentions found.
DuPont: No mentions found.
ExxonMobil: No mentions found.
GE: No mentions found.
Hewlett-Packard: No mentions found.
Home Depot: No mentions found.
Intel: No mentions found.
IBM: No mentions found.
JPMorgan: WSJ pC3 "JPMorgan settles in trading probe" by Ryan Tracy, Dan Fitzpatrick, WSJ pC1 "Scrutiny of banks widens" by Christian Berthelsen, Jamila Trindle, Dan Fitzpatrick, NYT pB1 "JJPMorgan looks to pay to settle US inquiries" by Jessica Silver-Greenberg, Ben Protess, FT p11 "JPMorgan to pay $410 m to settle pwoer market manipulation claim" by Tom Braithwaite, Gregory Meyer say JPMorgan will pay $410 mil to settle FERC energy manipulation charges.
Johnson & Johnson: No mentions found.
McDonald's: No mentions found.
Merck:WSJ pC4 "Dow industrials tip lower" by Tomi Kilgore says the Dow was down as investors balanced data showing a strong rise in home prices vs. a slip in consumer confidence & mixed corp earnings. Pfizer rose 13 cents after it reported 2Q earnings above analyst forecasts, offsetting rev that fell shy of forecasts. Merck fell 29 cents as earnings and rev dropped from year earlier levels.
NYT pB8 "merck profit plunges 50% as generics cut into sales" by AP, WSJ pB10 "Pfizer, Merck feel the pinch of generics" by Jonathan D. Rockoff, Peter Loftus, IBD pA1 "Drug giants' Q2 earnings fare better than forecasts" by Amy Reeves say lost patent protection on drugs hurt sales at Pfizer and Merck in 2Q. Pfizer's profit mroe than quadrupled to $14.1 bil but rev fell 7% to $12.97 bil, slightly below analyst estimates. Merck earned $906 mil or 30 cents a share down from $1.79 bil or 58 cents a year ago. Sales declined 11% to $11.01 bil. Sales of Singulair droped 80% to $281 mil after losing US patent protection.
FT p20 Pfizer boosted by strong earnings as pharmas support S&P 500" by Jason Abbruzzese says Pfixer and Merck highlighted the mixed earnings season as Pfizer reported 2Q earnings that beat estimates while Merck missed expectations on rev and earnings per share.
Microsoft: WSJ pC3 "Ex-analyst is charged for tipping off SAC" by Michael Rothfeld, Jenny Strasburg says the inside information was from an insider at Microsoft about Microsoft.
Pfizer: WSJ pC4 "Dow industrials tip lower" by Tomi Kilgore says the Dow was down as investors balanced data showing a strong rise in home prices vs. a slip in consumer confidence & mixed corp earnings. Pfizer rose 13 cents after it reported 2Q earnings above analyst forecasts, offsetting rev that fell shy of forecasts. Merck fell 29 cents as earnings and rev dropped from year earlier levels.
WSJ pB10 "Pfizer, Merck feel the pinch of generics" by Jonathan D. Rockoff, Peter Loftus, NYT pB8 "Pfizer settles a drug marketing case for $491 million" by Katie Thomas, FT p12 "Pfizer hit by patent expirations as sales fall 7%" by Andrew Jack, IBD pA1 "Drug giants' Q2 earnings fare better than forecasts" by Amy Reeves say lost patent protection on drugs hurt sales at Pfizer and Merck in 2Q. Pfizer's profit more than quadrupled to $14.1 bil but rev fell 7% to $12.97 bil, slightly below analyst estimates. Merck earned $906 mil or 30 cents a share down from $1.79 bil or 58 cents a year ago. Sales declined 11% to $11.01 bil. Sales of Singulair droped 80% to $281 mil after losing US patent protection.
FT p20 Pfizer boosted by strong earnings as pharmas support S&P 500" by Jason Abbruzzese says Pfixer and Merck highlighted the mixed earnings season as Pfizer reported 2Q earnings that beat estimates while Merck missed expectations on rev and earnings per share.
Procter & Gamble: No mentions found.
3M: No mentions found.
Travelers: No mentions found.
United Technologies: No mentions found.
UnitedHealth: No mentions found.
Verizon: WSJ pC2 "National rollout ready" by Robin Sidel says Isis, a jv, between AT&T, T-Mobile and Verizon, is a fledgling mobile payments system that will launch later this year.
Walmart: No mentions found.
Wednesday's Dow News followed by Tuesday's Closing Dow Numbers:
AT&T: WSJ pC2 "National rollout ready" by Robin Sidel says Isis, a jv, between AT&T, T-Mobile and Verizon, is a fledgling mobile payments system that will launch later this year.
Alcoa: No mentions found.
American Express: No mentions found.
Bank of America: No mentions found.
Boeing: No mentions found.
Caterpillar: No mentions found.
Chevron: NYT pC1 "An avenger on the defensive" by Clifford Krauss says the lawyer who beat Chevron in Ecudador and won an $18 bil judgment is defending himself against extortion charges brought by Chevron.
Cisco: No mentions found.
Coke: No mentions found.
Disney: No mentions found.
DuPont: No mentions found.
ExxonMobil: No mentions found.
GE: No mentions found.
Hewlett-Packard: No mentions found.
Home Depot: No mentions found.
Intel: No mentions found.
IBM: No mentions found.
JPMorgan: WSJ pC3 "JPMorgan settles in trading probe" by Ryan Tracy, Dan Fitzpatrick, WSJ pC1 "Scrutiny of banks widens" by Christian Berthelsen, Jamila Trindle, Dan Fitzpatrick, NYT pB1 "JJPMorgan looks to pay to settle US inquiries" by Jessica Silver-Greenberg, Ben Protess, FT p11 "JPMorgan to pay $410 m to settle pwoer market manipulation claim" by Tom Braithwaite, Gregory Meyer say JPMorgan will pay $410 mil to settle FERC energy manipulation charges.
Johnson & Johnson: No mentions found.
McDonald's: No mentions found.
Merck:WSJ pC4 "Dow industrials tip lower" by Tomi Kilgore says the Dow was down as investors balanced data showing a strong rise in home prices vs. a slip in consumer confidence & mixed corp earnings. Pfizer rose 13 cents after it reported 2Q earnings above analyst forecasts, offsetting rev that fell shy of forecasts. Merck fell 29 cents as earnings and rev dropped from year earlier levels.
NYT pB8 "merck profit plunges 50% as generics cut into sales" by AP, WSJ pB10 "Pfizer, Merck feel the pinch of generics" by Jonathan D. Rockoff, Peter Loftus, IBD pA1 "Drug giants' Q2 earnings fare better than forecasts" by Amy Reeves say lost patent protection on drugs hurt sales at Pfizer and Merck in 2Q. Pfizer's profit mroe than quadrupled to $14.1 bil but rev fell 7% to $12.97 bil, slightly below analyst estimates. Merck earned $906 mil or 30 cents a share down from $1.79 bil or 58 cents a year ago. Sales declined 11% to $11.01 bil. Sales of Singulair droped 80% to $281 mil after losing US patent protection.
FT p20 Pfizer boosted by strong earnings as pharmas support S&P 500" by Jason Abbruzzese says Pfixer and Merck highlighted the mixed earnings season as Pfizer reported 2Q earnings that beat estimates while Merck missed expectations on rev and earnings per share.
Microsoft: WSJ pC3 "Ex-analyst is charged for tipping off SAC" by Michael Rothfeld, Jenny Strasburg says the inside information was from an insider at Microsoft about Microsoft.
Pfizer: WSJ pC4 "Dow industrials tip lower" by Tomi Kilgore says the Dow was down as investors balanced data showing a strong rise in home prices vs. a slip in consumer confidence & mixed corp earnings. Pfizer rose 13 cents after it reported 2Q earnings above analyst forecasts, offsetting rev that fell shy of forecasts. Merck fell 29 cents as earnings and rev dropped from year earlier levels.
WSJ pB10 "Pfizer, Merck feel the pinch of generics" by Jonathan D. Rockoff, Peter Loftus, NYT pB8 "Pfizer settles a drug marketing case for $491 million" by Katie Thomas, FT p12 "Pfizer hit by patent expirations as sales fall 7%" by Andrew Jack, IBD pA1 "Drug giants' Q2 earnings fare better than forecasts" by Amy Reeves say lost patent protection on drugs hurt sales at Pfizer and Merck in 2Q. Pfizer's profit more than quadrupled to $14.1 bil but rev fell 7% to $12.97 bil, slightly below analyst estimates. Merck earned $906 mil or 30 cents a share down from $1.79 bil or 58 cents a year ago. Sales declined 11% to $11.01 bil. Sales of Singulair droped 80% to $281 mil after losing US patent protection.
FT p20 Pfizer boosted by strong earnings as pharmas support S&P 500" by Jason Abbruzzese says Pfixer and Merck highlighted the mixed earnings season as Pfizer reported 2Q earnings that beat estimates while Merck missed expectations on rev and earnings per share.
Procter & Gamble: No mentions found.
3M: No mentions found.
Travelers: No mentions found.
United Technologies: No mentions found.
UnitedHealth: No mentions found.
Verizon: WSJ pC2 "National rollout ready" by Robin Sidel says Isis, a jv, between AT&T, T-Mobile and Verizon, is a fledgling mobile payments system that will launch later this year.
Walmart: No mentions found.
Tuesday's Closing Dow Numbers:
Symbol  | Market | Last Sale | Net Change | % Change | Share Volume |
|---|---|---|---|---|---|
| AA | NYSE |  | 11,503,773 | ||
| AXP | NYSE |  | 3,324,112 | ||
| BA | NYSE | | 4,981,550 | ||
| BAC | NYSE | 70,973,547 | |||
| CAT | NYSE | | 4,878,556 | ||
| CSCO | NASDAQ-GS | | 45,280,204 | ||
| CVX | NYSE | | 4,046,128 | ||
| DD | NYSE | | 4,257,442 | ||
| DIS | NYSE | | 6,201,746 | ||
| GE | NYSE | | 31,038,883 | ||
| HD | NYSE | | 4,803,827 | ||
| HPQ | NYSE | | 13,085,979 | ||
| IBM | NYSE | | 2,247,579 | ||
| INTC | NASDAQ-GS | | 28,640,598 | ||
| JNJ | NYSE | | 8,828,112 | ||
| JPM | NYSE | | 14,065,157 | ||
| KO | NYSE | | 9,635,951 | ||
| MCD | NYSE | | 4,111,592 | ||
| MMM | NYSE | | 1,896,874 | ||
| MRK | NYSE | | 16,762,825 | ||
| MSFT | NASDAQ-GS | | 45,376,317 | ||
| PFE | NYSE | | 43,970,801 | ||
| PG | NYSE | | 6,407,932 | ||
| T | NYSE | | 17,558,570 | ||
| TRV | NYSE | | 2,184,173 | ||
| UNH | NYSE | | 5,343,219 | ||
| UTX | NYSE | | 2,956,685 | ||
| VZ | Dual Listed | | 11,522,166 | ||
| WMT | NYSE | | 4,509,849 | ||
| XOM | NYSE | | 10,427,431 |
**************
Here are the current CEOs of the Dow 30 Companies:
AT&T T Randall L. Stephenson (Dallas, TX)
Alcoa AA Klaus Kleinfeld (NY, NY)
American Express AXP Kenneth I. Chenault (NY, NY)
Bank of America BAC Brian T. Moynihan (Charlotte, N.C.)
Boeing BA W. James McNerney, Jr. (Chicago, Ill)
Caterpillar CAT Douglas Oberhelman (Peoria, Ill.)
Chevron CVX John Watson (San Ramon, CA)
Cisco CSCO John Chambers (San Jose, CA)
Coca Cola KO Muhtar Kent (Atlanta, GA)
Disney DIS Robert Iger (Burbank, CA)
DuPont DD Ellen Kullman (Wilmington, DE)
ExxonMobil XOM Rex W. Tillerson (Irving, Tx)
GE Jeffrey R. Immelt (Fairfield, CT)
Hewlett-Packard HPQ Meg Whitman (Palo Alto, CA)
Home Depot HD Frank Blake (Atlanta, GA)
Intel INTC Brian Krzanich (Santa Clara, CA)
IBM Virginia M. Rometty (Armonk, NY)
JPMorgan Chase JPM Jamie Dimon (NY, NY)
Johnson & Johnson JNJ Alex Gorsky (New Brunswick, NJ)
McDonald's MCD Donald Thompson (Oak Brook, Ill)
Merck MRK Kenneth Frazier (Whitehouse Station, N.J.)
Microsoft MSFT Steve Ballmer (Redmond, WA)
Pfizer PFE Ian Read (NY, NY)
Procter & Gamble PG A. G. Lafley (Cincinnati, OH)
3M MMM Inge Thulin (St. Paul, MN)
Travelers TRV Jay S. Fishman (NY, NY)
UnitedHealthUNC Stephen Hemsley (Minnetonka, MN)
United Technologies UTX Louis Chenevert (Hartford, CT)
Verizon VZ Lowell McAdam (NY, NY)
Wal-Mart WMT Mike Duke (Bentonville, ARK)
***************************
Here are the Dow Jones Industrial Average 30 as of 7/14/13 ranked in order of market capitalization in billions:
1. Exxon Mobil XOM $415.29
2. Microsoft MSFT 297.88
3. WalMart WMT 254.37
4. Johnson & Johnson JNJ 252.77
5. GE 245.68
6. Chevron CVX 240.55
7. Procter & Gamble PG 223.51
8. IBM 212.97
9. JPMorgan Chase JPM 208.30
10. Pfizer PFE 204.36
11. AT&T T 192.66
12. Coke KO 182.74
13. Bank of America BAC 148.55
14. Merck MRK 146.57
15. Verizon VZ 144.23
16. Cisco CSCO 138.63
17. Disney DIS 120.63
18. Intel INTC 118.81
19. Home Depot HD 117.65
20. McDonald's MCD 101.84
21. United Technologies UTX 91.77
22. American Express AXP 86.06
23. 3M MMM 79.47
24. Boeing BA 77.29
25. UnitedHealth UNH 69.36
26. Caterpillar CAT 57.31
27. Hewlett-Packard HPQ 50.51
28. DuPont DD 50.08
29. Travelers TRV 31.69
30. Alcoa AA 8.66
****************************************
Here are the latest 8K, 10Q & 10K & Proxy & certain other SEC filings as of 7/14/13:
Symbol & Co. Name/Date of Filing/Form Filed/ Comments
AT&T T: 7/12/13 8K re: AT&T agreeing to buy Leap Wireless
6/28/13 8K re: election of Cynthia B. Taylor as a Director & increase number of dirs. from 13 to 14
5/24/13 8K re: redemption of debentures
5/15/13 8K re: closing of sale of Global Notes due '43
5/3/13 10Q & 2 8Ks 4/23/13 re: 1 Qtr ended 3/31/13 results
4/29/13 8K re: voting results of annual stockholders meeting on 4/25/13
4/11/13 8K re: reclassification of revenue items
Alcoa AA: 7/11/13 & 7/9 8Ks re: 2Q earnings results
7/1/13 8K re: closing the Fusina, Italy aluminum smelter
5/30/13 8K re: Moody's downgrade of debt rating from Baa3 to Ba1 & from negative to stable
5/24/13 8K re: redemption of 65 Notes due 7/15/13
5/20/13 8K re: shut down of 2 smelters in Quebec
5/9/13 8K re: Sustainability Highlights Report
5/8/13 8K re: approval of Stock Incentive Plan
4/18/13 10Q; 4/11/3 8K & 4/9/13 8K all re: 1 Qtr ended 3/31/13 results
4/9/13 Proxy materials for 5/3/13 annual meeting of stockholders
American Express AXP: 6/21/13 8K re: selection of Jeffrey Campbell CFO
6/17/13 8K re: delinq. & write-off stats for 3 months thru 5/31/13
5/22/13 & 5/17/13 8Ks re: issuance of $1.85 bil of notes
5/15/13 8K re: delinq. & write-off stats for 3 months through 4/30/13
5/7/13 8K re: retirement of CFO Daniel T. Henry
5/2/13 8K re: voting results of 4/29 Sahreholder Meeting
4/30/13 8K re: increase in quarterly dividend from 20 cents to 23 cents per share
4/29/13 10Q & 4/17/13 8K re: 1Qtr ended 3/31/13 results
4/15/13 8K re: election of Edward P. Gilligan, Pres.
4/15/13 8K re: delinq. & write-off states for 3 months through 3/31
Bank of Am BAC: 7/2/13 8K re: redemption of securities
5/29/13 8K re: issuance of 40,000 shaes of Series U Preferred Stock
5/28/13 8K re: redemption of Perpetual Preferred Stock
5/8/13 8K re: voting results from 5/8 Stockholders Meeting
5/7/13 10Q & 4/17/13 8K re: 1 Qtr ended 3/31 results
5/6/13 8K re: settlement of lawsuit with MBIA
4/1/13 8K re: redemption of certain securities
Boeing BA: 5/3/13 8K re: issuance of floating rate senior notes due '14
4/30/13 8K re: voting results of 4/29 shareholders meeting held 4/29
4/24/13 10Q & 4/24/13 8K re: 1 Qtr. ended 3/31 results
4/22/13, 4/16 & 3/15/13 Proxy materials re: 4/29/13 annual mtg of shareholders at Field Museum, Chicago
Caterpillar CAT: 6/20/13 8K re: 3 month dealer stats thru 3/13
6/17/13 8K re: voting results of annual shareholderss mtg on 6/12
6/12/13 8K re: 15% increase in dividend from 8 cents to 60 cents payable 8/20 to record holders 7/22
5/20/13 8K re: 3 months dealer stats Feb through April 2013
5/17/13 8K re: settlement re: litigation arising from acquisition of ERA Mining (China)
5/2/13 10Q & 4/22/13 8K re: 1 Qtr ended 3/31/13 results
4/19/13 8K re: March dealer stats
4/10/13 8K re: retirement of G. Vittecoq, VP
Chevron CVX: 7/10/13 8K re: 2Q interim update
6/24/13 8K re: issuance of notes
6/4/13 8K re: approval by stockholders of Long Term Incentive Plan
5/2/13 10Q; 4/26/13 8K; 4/10/13 8K re: 1 Qtr ended 3/31/13 results
4/11/13 & 4/2/13 Proxy materials re: Stockholders meeting on 5/29
4/2/13 8K re: salary increase for CEO and other execs
Cisco CSCO: 6/20/13 8K: re: exec's pre-arranged stock trading plan
6/12/13 8K re: executives' adoption of pre-arranged stock trading plan
6/7/13 8K re: Cisco payment to Tivo of $294 mil to settle patent dispute that includes Google & AARIS Group
5/21/13 10Q for qtr ended 4/27/13
5/15/13 8K re: 3Q ended 4/27 results
Coke KO: 5/15/13 8K re: amendment of by-laws to allow calling of special shareholders meeting
4/26/13 10Q & 4/16/13 8K re: 1 Qtr ended 3/29 results
4/4/13 Proxy re: 4/24 shareholder meeting
Disney DIS: 7/1/13 8K re: extension of CEO Robert A. Iger's employment contract to 6/30/16
5/7/13 10Q & 8K re: 1 Qtr ended 3/30 results
3/20/13 8K re: $1.5 bil 364 day credit agreement
3/8/13 8K re: change to exec bonus plan
DuPont DD: 4/29/13 8K re: voting results of 4/24 stockholders meeting
4/23/13 10Q & 8K re: quarter ended 3/31 results
4/4 proxy materials
3/26/13 8K re: settlement with Monsanto of patent litigation
3/15/13 Proxy re: 4/24 Stockholders Meeting at DuPont Theatre, Wilmington, DE
ExxonMobil XOM: 6/3/13 8K re: voting results of 5/29/13 Annual Meeting of Shareholders
5/13/13; 5/10; 4/12 Proxy materials
5/2/13 10Q & 4/25/13 8K re: 1 Qtr. ended 3/31 results
3/26/13 8K re: financial presentation
3/12/13 8K re: analyst meeting
GE: 6/14/13 8K re: election of Keith S. Sherlin, CEO GE Capital
5/8/13 10Q & 4/19/13 8K re: 1 Qtr. ended 3/31 results
4/26/13 8K re: voting results of 4/24 shareholders meeting
4/8/13 Proxy materials for shareholders meetings
Hewlett-Packard HPQ: 6/18/13 8K re: change of duties of EVP R. Todd Bradley
6/6/13 10Q & 5/22/13 8K re: qtr ended 4/30/13
5/29/13 8K re: resignation of John H. Mammergren & G. Kennedy Thompson from BoD and temporary reduction of Board members from 11 to 9
4/4/13 8K re: resignations of directors John H. Hammergren & G. Kennedy Thompson
Home Depot HD: 5/29/13 8K re: shareholder approval of Amended Restated '05 Stock Incentive Plan
5/29/13 10Q & 5/21/13 8K re: qtr ended 5/5/13
4/8/13 Proxy materials for 5/23 shareholders meeting at Cobb Galleria, Atlanta
4/5/13 8K re: issuance of 2.7% Sr. Notes due '23 & '43
Intel INTC: 5/21/13 8K re: Brian M. Krzanich became CEO on 5/16
5/8/13 Proxy materials
5/2/13 8K re: election of Brian M. Krzanich as CEO Z& Renee J. James as pres. effective 5/16
4/29/13 10Q & 4/17 8K & 4/16 8K re: results of 1st quarter ended 3/30
4/3/13 Proxy materials for 5/16 stockholders meeting at Santa Clara, Cal.
IBM: 5/6/13 8K re: issuance of notes
5/3/13 8K re: retirement of SVP HR J. Randall MacDonald
4/30/13 10Q & 4/19/13 & 4/18/13 8Ks re: 1 Qtr ended 3/31 results
4/3/13 Proxy materials
3/11/13 Proxy re 4.30/13 annual meeting of stockholders at Von Braun Ctr., Huntsville, Al
JPMorganChase JPM: 7/12/13 2 8Ks re: 2Q results
6/10/13 8K re: amendment to Cert. of Incorp. to allow shareholder action by written consent
6/4/13 8K re: Reg FD disclosure re: investor conference presentation
5/23/13 8K re: results of 5/21/13 Annual Shareholders Meeting
5/16/13 Proxy materials for 5/21 shareholders meeting
5/15/13 8K re: sale of 1.6% notes due '18
5/8/13 10Q & 4/12 8K re: 1Q ended 3/31 results
5/2/13 8K re: sale of 4.25% notes due '18
4/23/13 8K re: sale of notes
5/1/13 8K re: sale of notes
4/29/13 8K re: resignation of co-C Frank J. Bisignano
4/9/13 8K re: redemption of securities
Johnson & Johnson JNJ: 6/20/13 8K re: agreement to buy Aragon Pharmaceuticals, Inc. for its late state prostate drugs
5/3/13 10Q & 4/16 8K reL: 1 Qtr ended 3/31 results
4/26/13 8K re: voting results of 4/25 shareholders meeting
3/13/13 Proxy re: 4/25/13 Shareholder mtg at Hyatt New Brunswick, NJ
McDonald's MCD: 6/10/13 8K re: Reg. FD disclosure re: Investor Release
5/28/13 8K re: voting results of 5/23/13 Annual Shareholders Meeting
5/8/13 8K re: April sales
5/6/13 8K re: issuance of notes
5/3/13 8K re: adjustment to sales results
Merck MRK: 5/30/13 8K re: voting results of 5/28/13 Annual Meeting of Shareholders
5/22/13 8K re: accelerated stock repurchase agreement with Goldman Sachs
5/20/13 8K re: issuance of $6 bil of notes
Microsoft MSFT: 7/11/13 8K re: resignation of Pres. of Office Div. Kurt DelBene
7/3/13 8K re: retirement of Steve Sinofsky from Windows Div.
5/20/13 8-K/A approval of CFO Amy Hood's compensation
5/13/13 8K re: election of Amy Hood as CFO
5/1/13 8K re: sale of Euro notes
4/18/13 8K re: resignation of CFO Peter Klein
4/18/13 10Q & 4/18 8K re: results of Qtr ended 3/31
Pfizer PFE: 6/3/13 8K re: issuance of $4 bil of notes
5/29/13 8K re: blackout of insider purchase of shares due to Zoetis exchange offer
5/10/13 10Q & 4/30/13 8K re: 1 Qtr ended 3/31 results
4/29/13 8K re: voting results of 4/25/13 shareholders meeting
4/3/13 Proxy material
Procter & Gamble PG: Pre-14A Proxy re: Annual Meeting of Shareholders on 10/8/13 at Aronoff Center in Cincinnati
7/9/13 8K re: declaration of dividend of $0.6015 on Common & Conv. Call A Pref. payable 8/15 to 7/19 record holders
6/12/13 8K re: Reg. FD disclosure re: presentation at Deutsche Bank Global Consumer Conference
6/5/13 8K re: grouping of Global Business Units into 4 industry based sectors
5/24/13 8K re: A.G. Lafley rejoining as CEO replacing Bob McDonald
5/14/13 8K re: Reg. FD disclosure re: Goldman Sachs Consumer Products Symposium
4/24/13 10Q & 4/24 2 8Ks re: 3Q ended 3/31 results
4/15/13 8K re: quarterly dividend of 0.6015 cents per share
3M MMM: 5/16/13 8K re: amendment to Annual Report re: realignment of business groups and certain accounting revisions
5/15/13 8K re: voting results of 5/14 stockholders meeting
5/7/13 Proxy materials
5/2/13 10Q & 4/25/13 8K re: 1 Qtr ended 3/31 results
Travelers TRV: 6/12/13 8K re: $1 bil revolving bank credit agreement
6/10/13 8K re: purchase of Dominion of Canada General Insurance for $1.1 bil
5/24/13 8K re: voting results of 5/22/13 Annual shareholders meeting
4/23/13 10Q & 4/23/13 8K re: qtr ended 3/31 results
4/9/13 Proxy for 5/22 shareholders meeting at Hartford, Ct.
United Technologies UTX: 6/18/13 8K re: Ohio Fed. Ct. awarding $473 mil to U.S. re: False Claims Act re: overcharging by Pratt & Whitney on F100's
5/24/13 8K re: redemption of $1 bil 1.2% notes due 6/1/13
4/30/13 8K re: results of shareholders meeting
4/26/13 10Q & 4/23/13 8K re: 1 Qtr ended 3/31 results
4/9/13 Proxy materials for 4/29 annual shareholders meeting
UnitedHealth Group UNH: 6/6/13 8K re: Voting results of 6/3/13 Annual Shareholders Mtg
5/29/13 8K re: Reg FD disclosure re: Bernstein 29th Annual Strategic Decisions Conference
5/6/13 10Q & 4/18/13 8K re: 1 Qtr ended 3/31 results
4/24/13 Proxy materials for 6/3 shareholders meeting in Boston
3/11/13 8K re: Barclays Global Healthcare conference presentation
2/28/13 8K re: sale of Notes
2/7/13 10K for year ended 12/31/12
Verizon Communications Inc. VZ: 6/10/13 8K re: election of Anthony T. Skiadas, 44, Sr. VP & Controller
5/13/13 8K re: distribution of $7 bil to Wireless Comm and Vodafone by Verizon Wireless
5/7/13 8K re: voting results of 5/2 annual mtg of shareholders
4/25/13 10Q & 4/13/13 8K re results of quarter ended 3/31
4/2/13 8K re: rumors of purchase of Vodaphone's interest in Verizon Wireless
4/1/13 & 3/18/13 Proxy re: 5/2/13 Annual Mtg of shareholders, Doubletree, Tulsa, OK
2/26/13 10K for year ended 12/31/12
2/7/13 8K re: election of Gregory D. Wasson, Pres & CEO of Walgreen, as Director
WalMart WMT: 6/7/13 10Q & 5/16/13 8K re: Qtr. ended 4/30
6/2/13 8K re: Voting results of 6/7 Annual shareholder meeting
4/22/13 Proxy re: 6/7 shareholder meeting at Fayetteville, Ark.
4/10/13 8K re: sale of notes
3/26/13 10K for year ended 1/31/13
2/21/13 8K re: 4Q results & dividend for FY 2014
END END
No comments:
Post a Comment